Early Detection and Diagnosis of Pancreatic Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Biomarkers".
Deadline for manuscript submissions: closed (30 September 2022)
Special Issue Information
Dear Colleagues,
Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer deaths in Western countries and one of the most lethal of the common cancers. The disease is almost always detected at an advanced stage. This makes curative interventions difficult and contributes to the extremely poor 5-year survival rate of 3% to 15%. The late detection of PDAC can be attributed to a number of factors, including complex underlying biology, vague symptoms which overlap with a variety of benign diseases, a lack of biomarkers that are validated for early detection, and the absence of imaging techniques that can detect precancerous lesions with accuracy. While screening is recommended in high-risk groups, the fact that PDAC is relatively uncommon and that accurate detection tests are not available means that screening of asymptomatic individuals in the general population is not feasible.
It is recognized that early cancer detection reduces mortality, and currently, there is a wave of interest in finding ways to detect PDAC earlier. This Special Issue will highlight recent progress with regard to high-risk groups, biomarker development, as well as advances in imaging and prediction modeling.
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pancreatic cancer
- biomarkers
- early detection
- PanIN
- artificial intelligence
- imaging
- IPMN
- cystic lesion
- type 3c diabetes
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
